From WikiProjectMed
Jump to navigation Jump to search
Monoclonal antibody
TypeWhole antibody
Clinical data
Other namesREGN421
ATC code
  • none
CAS Number
  • none

Enoticumab (REGN421, INN) is a human monoclonal antibody that binds to DLL4. It acts as an immunomodulator.[1][2][3][4][5]


  1. ^ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).
  2. ^ Huang J, Hu W, Hu L, Previs RA, Dalton HJ, Yang XY, Sun Y, McGuire M, Rupaimoole R, Nagaraja AS, Kang Y, Liu T, Nick AM, Jennings NB, Coleman RL, Jaffe RB, Sood AK (June 2016). "Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth". Mol. Cancer Ther. 15 (6): 1344–52. doi:10.1158/1535-7163.MCT-15-0144. PMC 4893925. PMID 27009216.
  3. ^ Kuhnert F, Chen G, Coetzee S, Thambi N, Hickey C, Shan J, Kovalenko P, Noguera-Troise I, Smith E, Fairhurst J, Andreev J, Kirshner JR, Papadopoulos N, Thurston G (October 2015). "Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer". Cancer Res. 75 (19): 4086–96. doi:10.1158/0008-5472.CAN-14-3773. PMID 26377940.
  4. ^ Chiorean EG, LoRusso P, Strother RM, Diamond JR, Younger A, Messersmith WA, Adriaens L, Liu L, Kao RJ, DiCioccio AT, Kostic A, Leek R, Harris A, Jimeno A (June 2015). "A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors". Clin. Cancer Res. 21 (12): 2695–703. doi:10.1158/1078-0432.CCR-14-2797. PMID 25724527.
  5. ^ Miles KM, Seshadri M, Ciamporcero E, Adelaiye R, Gillard B, Sotomayor P, Attwood K, Shen L, Conroy D, Kuhnert F, Lalani AS, Thurston G, Pili R (2014). "Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts". PLOS ONE. 9 (11): e112371. Bibcode:2014PLoSO...9k2371M. doi:10.1371/journal.pone.0112371. PMC 4231048. PMID 25393540.